Clinical trials: Chronic Systolic Heart Failure
Chronic Heart Failure
SYNCHRO. Evaluation of the Forecasts Parameters of Real Time-three-dimensional Doppler Echocardiography in Selecting Patients With Chronic Heart Failure for Cardiac Resynchronisation Therapy
Patients showing a normal value of SDI (< or + 8%) will randomly be assigned to CRT in "ON" or "OFF"mode at one month after implantation.
- Trial name
- NCT00488410
- Testing
- Doppler echocardiography
- Where
- France
- Sponsor
- University Hospital, Clermont-Ferrand
Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT06108076
- Testing
- Ketone Monoester (KE)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Diastolic Dysfunction, Heart Failure
Aerobic Versus Combined Exercise and Diastolic Dysfunction
Thirty-two stable patients with chronic heart failure participated in an exercise rehabilitation program. They randomly assigned to aerobic exercise (AER) or combined aerobic and strength training (COM).
- Trial name
- NCT04916184
- Testing
- aerobic exercise, combined exercise
- Where
- Greece
- Volunteers
- 32 people
- Sponsor
- Evangelismos Hospital
Chronic Systolic Heart Failure, Paroxysmal VT
Cardiac MRI for Optimal Heart Failure Outcomes With CRT Upgrades
This study will investigate the use of cardiac MRI in patients with standard ICDs and pacemakers to inform how cardiac resynchronization therapy (CRT) can best be implemented in these patient and which patients are the best…
- Trial name
- NCT03504891
- Testing
- MRI prior to CRT Upgrade, MRI prior to de novo CRT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Virginia
Systolic Heart Failure, Iron Deficiency
Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
The purpose of this study is to determine whether intravenous iron supplementation using ferric carboxymaltosis (FCM) extends the time-to-first-event of heart failure hospitalisations and cardiovascular (CV) death and reduces…
- Trial name
- FAIR-HF2 (NCT03036462)
- Testing
- Iron, Saline
- Where
- 51 sites in Germany, Hungary and 5 more
- Volunteers
- 1,105 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Congestive Heart Failure
Effects of Pentoxiphylline on Left Ventricular (LV) Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure (CHF)
This is a prospective, double blinded randomized clinical study to evaluate the Effects of Pentoxifylline on left ventricular systolic function indices and circulating biomarkers in patients with chronic congestive heart failure.
- Trial name
- PENT-CHF (NCT01337349)
- Testing
- Pentoxifylline
- Where
- United States
- Sponsor
- Henry Ford Health System
Heart Failure, Congestive
Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5
The purpose of this study is to determine whether treatment with the OPTIMIZER System is safe and effective in patients with moderate to severe heart failure symptoms.
- Trial name
- NCT00112125
- Testing
- OPTIMIZER System
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Impulse Dynamics
Heart Failure, Systolic
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes…
- Trial name
- PROVIDE-HF (NCT03387163)
- Testing
- Sacubitril/Valsartan
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Preserved Systolic Function
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart…
- Trial name
- PRESERVED-HF (NCT03030235)
- Testing
- Dapagliflozin 10Mg Oral Tablet
- Where
- 26 sites in United States
- Volunteers
- 324 people
- Sponsor
- Saint Luke's Health System
Chronic Systolic Heart Failure
Effect of Remote Ischemic Conditioning in Patients With Chronic Ischemic Heart Failure
The present study will evaluate whether treatment with daily remote ischemic conditioning for a 28±4-day period induces beneficial effects in subjects with and without chronic ischemic heart failure in terms of improved left…
- Trial name
- CONDI-HF (NCT02248441)
- Testing
- Daily ischemic conditioning treatment
- Where
- Denmark
- Volunteers
- 47 people
- Sponsor
- University of Aarhus
Heart Failure, Systolic, Renal Disease, End Stage
Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease
Interleukin-1 blockade for the treatment of heart failure in patients with advanced chronic kidney disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a Phase 2, single-arm trial designed to…
- Conditions
- Heart Failure, Systolic, Renal Disease, End Stage, Chronic Kidney Diseases
- Trial name
- E-HART (NCT03062176)
- Testing
- Anakinra
- Sponsor
- Virginia Commonwealth University
Systolic Heart Failure, Myocardial Disease
Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
Accumulated clinical and experimental data suggest that dysfunctional coronary microcirculation plays a pivotal role in the progression of heart failure despite an optimal therapy used.
- Conditions
- Systolic Heart Failure, Myocardial Disease, Cardiomyopathy
- Trial name
- NCT00348530
- Testing
- Verapamil
- Where
- Poland
- Volunteers
- 120 people
- Sponsor
- Medical University of Silesia
Systolic Heart Failure
Pilot Study Using Echocardiography to Evaluate Patients With Heart Failure and Dyssynchrony Who Have a CRT-D Device
Out of all the patients that receive a CRT-D ( a dual chamber pacemaker with defibrillator ) for cardiac resynchronization therapy there is approximately one-third that do not respond.
- Trial name
- NCT01127334
- Where
- United States
- Sponsor
- University of Mississippi Medical Center
Heart Failure
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction.
- Trial name
- QUID-HF (NCT02780180)
- Testing
- QGC001
- Where
- 23 sites in Czechia, France and 6 more
- Volunteers
- 23 people
- Sponsor
- Quantum Genomics SA
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
Heart Failure
V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure
The purpose of the trial is to evaluate the safety, usability and performance of the V-LAP™ System in adult subjects with New York Heart Association (NYHA) Class III Heart Failure.
- Trial name
- VECTOR-HF (NCT03775161)
- Testing
- V-LAP™ System
- Where
- 2 sites in Germany, Italy
- Volunteers
- 45 people
- Sponsor
- Vectorious Medical Technologies Ltd.
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic…
- Conditions
- Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure
- Trial name
- COSMIC-HF (NCT01786512)
- Testing
- Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Omecamtiv Mecarbil Swellable Core Technology F2
- Where
- 101 sites in United States, Australia and 11 more
- Volunteers
- 544 people
- Sponsor
- Cytokinetics
Heart Failure
Multiple Dose Study in Heart Failure of BAY 1067197
This is a study to investigate the safety, tolerability and early effects on cardiac function of the partial A1 agonist BAY1067197 in patients with chronic heart failure.
- Trial name
- PARSiFAL (NCT02040233)
- Testing
- BAY1067197 (10 mg), BAY1067197
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Bayer
Heart Failure, Congestive
ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy
The purpose of this study is to test the safety and efficacy of the Celacade™ system in reducing the risk of mortality and cardiovascular hospitalizations in patients with chronic systolic heart failure.
- Trial name
- NCT00111969
- Testing
- Celacade™ system
- Volunteers
- 2,016 people
- Sponsor
- Vasogen